• News
  • Europe

MindMaze Therapeutics Secures CHF 4 Million Financing

Funding will support wider commercial deployment of its neurotherapeutics platform.

11/17/2026
•Ali Abounasr El Alaoui
Back to News

MindMaze Therapeutics has secured investment commitments of up to CHF 4 million from long-term strategic investors. The company develops precision neurotherapeutics and trades on the SIX exchange. The funding will support wider commercial deployment of its neurotherapeutics platform.


Financing terms

The agreements provide CHF 3 million in funding scheduled for November and December 2026. The closing remains subject to customary conditions. Either party may exercise an additional CHF 1 million investment option until February 28, 2027.

Commercial expansion

MindMaze already has a commercial organization in place. It plans to expand its customer base and accelerate revenue growth across its portfolio. The company also wants to broaden access to rehabilitation at home.

MindMotion Lite

The company is launching MindMotion Lite, a tablet-based solution designed for home deployment. It supports rehabilitation at home and is part of the wider portfolio. Healthcare providers are a key target for adoption.


The financing comprises primarily shares and mandatory convertible notes priced at CHF 0.12 per share, subject to a limited market-based adjustment. It includes 7 million five-year warrants at CHF 0.25 per share and 1.28 million five-year warrants at CHF 0.12. The company also agreed to terminate the remaining CHF 4 million unfunded commitment from a May 26, 2026 financing.